HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $7 to $10.
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $7 to $10.